MGI Tech and SeqOne Join Hands To Advance Complete Genomic Analysis

MGI, an organization focused on building center instruments and advances that drive development in life science, declared partnership with SeqOne, a leading provider of artificial intelligence driven genomic choice support software, to create and approve complete genomic analysis solutions from test to report custom fitted to the requirements of human genetics and pathology labs worldwide.

A routine workflow using Agilent panels, Magnis lib prep automation, MGI DNBSEQ-G99, and SeqOne somaHRD, a clinically validated HRD signature solution, will be technically validated by a Pathology Reference Lab in Spain, Agilent Technologies, MGI, a biotechnology firm and SeqOne.

The complete solution for pathology molecular labs will empower top caliber, proficient, and adaptable HRD testing around the world, including Genomic Instability score and BRCA testing. Empowering and approving SeqOne tertiary analysis solution viable with MGI Megabolt for Germline Boards, Entire Exome and Entire Genome.

The self-developed and MPS-concentrated hardware accelerating system developed by MGI, MegaBOLT bioinformatics analysis accelerator, is intended to guarantee compatibility and seamless integration with SeqOne's AI-powered variants identification and analysis solution. MegaBOLT and the SeqOne Platform will be combined in this project to provide a flexible, cost-effective, user-friendly, and time-saving sample-to-report solution that is especially appealing to high-throughput human genetics labs.